Related Experiment Videos
Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains
W H Berrettini1, T N Ferraro, R C Alexander
1Department of Psychiatry and Human Behavior, Jefferson Cancer Institute, Philadelphia, Pennsylvania.
Nature Genetics
|May 1, 1994
Summary
Researchers mapped genes linked to oral morphine preference in mice using quantitative trait loci (QTL) analysis. Three major genetic loci on chromosomes 1, 6, and 10 explain most of the observed differences in morphine consumption between mouse strains.
Area of Science:
- Genetics
- Neuroscience
- Pharmacology
Background:
- Opioid addiction is a complex trait influenced by genetic factors.
- Understanding the genetic basis of drug preference is crucial for developing targeted treatments.
Purpose of the Study:
- To identify quantitative trait loci (QTL) associated with oral morphine preference in mice.
- To determine the chromosomal locations of genes contributing to morphine consumption differences between C57BL/6J and DBA/2J mouse strains.
Main Methods:
- Quantitative trait loci (QTL) mapping was employed using an F2 intercross population (n=606) derived from C57BL/6J and DBA/2J mice.
- Mice were phenotyped for oral morphine preference using a two-bottle choice paradigm.
- Genotyping was performed using 157 murine microsatellite polymorphisms on mice exhibiting extreme morphine consumption.
Main Results:
- Three significant QTLs influencing oral morphine preference were identified on murine chromosomes 1, 6, and 10.
- These three loci collectively account for approximately 85% of the genetic variance in morphine preference between the parental strains.
- The identified loci provide a genetic map for genes modulating opioid reward behavior.
Conclusions:
- Genetic factors significantly contribute to individual differences in oral morphine preference.
- The identified QTLs represent key genomic regions for further investigation into the neurobiological mechanisms of opioid reward and addiction.
- This study provides a foundation for future research into the genetic architecture of substance use disorders.